#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15842	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2100	747.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1429	1429	C	928	C	876	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15842	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2100	747.0	0	HET	.	.	.	C1200T	.	1200	1200	C	1445	1445	C	906	C,T	652,210	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3602	806.8	0	.	n	.	0	T695C	SNP	695	695	T	1095	1095	C	850	C,T	808,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3602	806.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1737	1737	A	1033	A	988	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3602	806.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2371	2371	C	963	C,T	910,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3602	806.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2997	2997	T	901	T,C	852,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3602	806.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2445	2445	A	934	A	899	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2240	folP	852	852	100.0	folP.l15.c4.ctg.1	1681	132.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1092	1094	AGC	204;204;203	A;G;C,A	200;198;198,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6064	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3434	175.8	1	SNP	p	S91F	0	.	.	271	273	TCC	552	554	TCC	213;211;212	T;C;C	199;198;199	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6064	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3434	175.8	1	SNP	p	D95N	0	.	.	283	285	GAC	564	566	GAC	210;204;207	G;A,G;C	193;187,1;189	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6064	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3434	175.8	1	SNP	p	D95G	0	.	.	283	285	GAC	564	566	GAC	210;204;207	G;A,G;C	193;187,1;189	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1892	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1404	134.0	0	.	p	.	0	A39T	NONSYN	115	117	GCC	505	507	ACC	234;235;233	A;C;C	216;221;220	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1892	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1404	134.0	0	.	p	.	0	R44H	NONSYN	130	132	CGC	520	522	CAC	215;216;215	C;A;C	203;203;203	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1892	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1404	134.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	703	705	CAC	218;217;213	C;A;C	212;209;208	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1892	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1404	134.0	1	SNP	p	G45D	0	.	.	133	135	GGC	523	525	GGC	215;213;215	G;G;C	201;203;202	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1062	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	975	107.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6134	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3180	192.2	1	SNP	p	D86N	0	.	.	256	258	GAC	719	721	GAC	235;233;234	G;A;C	227;220;228	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6134	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3180	192.2	1	SNP	p	S87I	0	.	.	259	261	AGT	722	724	AGT	235;232;232	A,C;G;T	222,1;224;224	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6134	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3180	192.2	1	SNP	p	S87W	0	.	.	259	261	AGT	722	724	AGT	235;232;232	A,C;G;T	222,1;224;224	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6134	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3180	192.2	1	SNP	p	S87R	0	.	.	259	261	AGT	722	724	AGT	235;232;232	A,C;G;T	222,1;224;224	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6134	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3180	192.2	1	SNP	p	S88P	0	.	.	262	264	TCC	725	727	TCC	235;239;243	T;C;C	225;228;234	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4700	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2560	182.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1506	1508	GGC	246;246;242	G,T;G;C	234,1;231;224	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1272	1274	GCA	261;261;261	G,A;C;A	239,1;243;247	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1275	1277	ATC	257;258;260	A;T;C	244;245;243	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1287	1289	GTG	273;271;273	G;T;G	260;258;261	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1287	1289	GTG	273;271;273	G;T;G	260;258;261	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1791	1793	ACC	242;240;240	A;C;C	226;229;226	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1845	1847	GCG	221;219;218	G,A;C,G;G	197,1;170,1;186	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1845	1847	GCG	221;219;218	G,A;C,G;G	197,1;170,1;186	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1968	1970	GGC	171;172;172	G;G;C	166;166;164	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1977	1979	GGC	167;166;164	G;G;C	162;159;158	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4648	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	189.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1995	1997	CCG	151;157;156	C,CG;C;G	124,1;130;131	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6812	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3089	219.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2512	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1825	136.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	568	568	C	165	C	156	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	501	503	GGA	287;287;285	G;G;A	272;273;268	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	0	.	p	.	0	T87A	NONSYN	259	261	ACT	618	620	GCT	268;269;271	G,A;C;T	239,2;244;240	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	0	.	p	.	0	F135L	NONSYN	403	405	TTT	762	764	CTT	226;224;228	C,T;T;T	212,1;211;215	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	786	788	GGA	242;242;240	G;G;A	228;227;221	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	0	.	p	.	0	D171G	NONSYN	511	513	GAT	870	872	GGT	232;231;232	G,T;G;T	219,1;217;210	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	0	.	p	.	0	G189S	NONSYN	565	567	GGC	924	926	AGC	257;258;254	A;G;C,T	239;242;238,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	990	990	T	256	T	244	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	1	SNP	p	G120K	0	.	.	358	360	GGT	717	719	GGT	232;230;228	G;G;T	221;217;212	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	1	SNP	p	A121N	0	.	.	361	363	GCC	720	722	GCC	226;227;227	G;C;C,A	213;217;218,2	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3288	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1557	210.0	1	SNP	p	A121D	0	.	.	361	363	GCC	720	722	GCC	226;227;227	G;C;C,A	213;217;218,2	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12692	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4829	261.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2004	2006	AAT	287;287;289	A;A;T	272;273;274	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1438	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1103	129.7	1	SNP	p	V57M	1	.	.	169	171	ATG	466	468	ATG	297;295;296	A;T;G	283;281;276	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
